Abbott Labs Faces a Test on July 16 After FDA Clearance and Deal Costs

Abbott Laboratories (NYSE: ABT) reports second-quarter earnings on July 16, and the stock carries an Alpha Score of 34 out of 100 – a Weak label that suggests the quantitative model sees more risk than reward at current levels. The print lands less than three weeks after the FDA cleared safety findings tied to the Sturgis baby formula plant, removing a regulatory overhang that had lingered since early 2022. That clearance lifts a direct drag on Abbott's nutrition business. It does not fix the margin pressure in diagnostics or the dilution from the Exact Sciences deal.

The diagnostics division, Abbott's largest revenue segment, has been a mixed bag. The company cut its full-year adjusted EPS guidance when it closed the Exact Sciences acquisition in April, a move that overshadowed a first-quarter revenue beat. Management framed the lower forecast as a temporary integration cost. The market sold off on the news – shares dropped 3.5% the day the deal closed. The diagnostics unit still faces volume normalization after the pandemic pull-forward, and hospital pricing power remains constrained. Investors heading into the July 16 report will want to see whether adjusted operating margins in diagnostics can hold above 25%.

The medical devices segment, by contrast, has been a steady contributor. Abbott's structural heart and electrophysiology lines have grown mid-single digits each quarter, and the company sees a tailwind from the aging U.S. population. The FDA clearance on baby formula also protects the nutrition segment from further operational surprises: the plant restart removes the single biggest supply-chain uncertainty in that business. Nutrition margins are still recovering from the plant shutdown and the subsequent voluntary recall. A full rebound will take several more quarters.

The Weak Alpha Score reflects a combination of mediocre earnings quality scores, elevated valuation relative to historical multiples, and below-average momentum. The model does not incorporate soft factors like the FDA clearance or the exact timing of the Exact Sciences integration, so the score is a baseline, not a verdict. Still, a stock with a sub-40 score that is trading at 23x forward earnings leaves little room for execution error. Any miss on the Q2 top line or a downward revision to the second-half outlook could accelerate the selloff.

What changed the investment case more than the Q2 guidance itself was the shape of the Exact Sciences deal. Abbott paid about $9.3 billion in cash and stock for the molecular diagnostics company, a price that some analysts at the time described as full. The combined business gives Abbott a stronger presence in cancer testing. It also adds roughly $1.5 billion in net debt. Free cash flow covers the interest cost comfortably. Leverage above 1.5x debt-to-EBITDA leaves less flexibility for buybacks or dividend growth this year. Abbott raised its dividend for the 51st consecutive year in March, and the payout ratio ticked up to 63% – manageable, not expanding.

The July 16 quarter is the first full-period report that includes the Exact Sciences acquisition, so the organic growth picture will be muddied by deal accounting. Management has not given explicit organic guidance for the unit. The consensus expects diagnostics revenue to grow about 4% year-over-year on a pro-forma basis. The medical devices segment is the cleaner read-through: if structural heart sales accelerate past 6%, the stock could hold its recent $115-120 range. If they decelerate, the Weak Alpha Score may prove prescient.

The next concrete check after the print is the August investor day, where Abbott plans to give a longer-term outlook for the combined portfolio. Until then, the Q2 report sets the tone.